Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report).

In the trading week from November 4th to 8th, experts opinion is between volatile to bearish in Dow Jones, S&P 500, and ...

A set of 5700 free MIT-licensed high-quality SVG icons for you to use in your web projects. Each icon is designed on a 24x24 grid and a 2px stroke.

Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.27%.

As of October 28, 2024, Vertex Pharmaceuticals Incorporated had a $123.0 billion market capitalization, putting it in the 98th percentile of companies in the Biotechnology industry. Vertex ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Deep-pocketed investors have adopted a bullish approach towards Vertex Pharmaceuticals VRTX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

VRTX will need to target hospitals and surgical centers as well as physicians' offices. Marketing will involve working with hospitals to gain formulary access through the Pharmacy & Therapeutics ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral ...